Results 51 to 60 of about 77,471 (339)

Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies [PDF]

Journal of Immunotherapy and Precision Oncology
AT-rich interaction domain 1A (ARID1A), a mammalian switch/sucrose nonfermenting complex subunit, modulates several cellular processes by regulating chromatin accessibility.
Kyaw Z. Hein, Bettzy Stephen, Siqing Fu
doaj   +1 more source

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

npj Breast Cancer, 2022
We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC).
Ilenia Migliaccio, Marta Paoli, Emanuela Risi, Chiara Biagioni, Laura Biganzoli, Matteo Benelli, Luca Malorni   +6 more
doaj   +1 more source

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

Journal of Clinical Oncology, 2022
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations.
S. Damodaran, Fengmin Zhao, D. Deming, E. Mitchell, J. Wright, R. Gray, V. Wang, L. McShane, L. Rubinstein, D. Patton, P. Williams, S. Hamilton, J. Suga, B. Conley, C. Arteaga, L. Harris, P. O'Dwyer, Alice P. Chen, K. Flaherty   +18 more
semanticscholar   +1 more source

Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma [PDF]

Mol Oncol
Spatially resolved analysis revealed heterogeneous distributions of selected cancer‐associated mutations within ovarian endometrioid carcinomas. Shared mutations between paired endometrial and ovarian tumors supported clonal relatedness. These findings highlight the value of sampling multiple tumor regions when interpreting molecular profiles ...
Ashihara T, Murakami K, Takamatsu S, Kanto A, Mori S, Otani T, Sakai K, Kotani Y, Nishio K, Abiko K, Matsumura N.   +10 more
europepmc   +2 more sources

Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus

bioRxiv, 2022
The PIK3CA gene is one of the most frequently mutated genes in all of human cancer. Here authors describe the molecular mechanisms underlying how different oncogenic mutations in PIK3CA mediate increased activity.
M. Jenkins, Harish Ranga-prasad, Matthew A. H. Parson, N. J. Harris, M. K. Rathinaswamy, J. Burke   +5 more
semanticscholar   +1 more source

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

New England Journal of Medicine
BACKGROUND In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus palbociclib–fulvestrant, among patients with ...
K. Jhaveri, Seock-Ah Im, C. Saura, S. Loibl, K. Kalinsky, P. Schmid, S. Loi, E. Thanopoulou, N. Shankar, Yanling Jin, T. Stout, Tiffany D. Clark, Chunyan Song, D. Juric, N. Turner   +14 more
semanticscholar   +1 more source

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Frontiers in Oncology, 2021
Despite the significant achievements in the diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease.
Nicola Fusco, U. Malapelle, M. Fassan, C. Marchiò, S. Buglioni, S. Zupo, C. Criscitiello, P. Vigneri, A. D. Dei Tos, E. Maiorano, G. Viale   +10 more
semanticscholar   +1 more source

PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. [PDF]

PLoS ONE, 2014
AIMS:To evaluate PIK3CA gene mutations and PIK3CA expression status in Chinese esophageal squamous cell carcinoma (ESCC) patients, and their correlation with clinicopathological characteristics and clinical outcomes. METHODS:Direct sequencing was applied
Lin Wang, Ling Shan, Shaokai Zhang, Jianming Ying, Liyan Xue, Yanling Yuan, Yongqiang Xie, Ning Lu   +7 more
doaj   +1 more source

MAPK and AKT pathway inactivation by cetuximab-KRAS- and cetuximab-PIK3CA-esiRNA treatment.

, 2018
Tumor lysate samples from xenograft experiments were processed for SDS PAGE and probed in Western blots for expression of KRAS downstream MAPK pathway effector phospho-ERK and PIK3CA downstream phospho-AKT along with their unphosphorylated (total ...
Wolfgang Hartmann (38453), Lisa Terheyden (5508857), Carsten Müller-Tidow (105305), Sebastian Bäumer (553210), Eva Wardelmann (387825), Jan Rehkämper (5508854), Nicole Bäumer (214974), Wolfgang E. Berdel (106792), Neele Appel (5508851), Frank Buchholz (166464)   +9 more
core   +1 more source

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib

Journal of Experimental Medicine, 2022
Here, the authors report the first description of two infants with PIK3CA-related overgrowth spectrum treated by alpelisib. Patients were monitored with pharmacokinetics. Alpelisib was associated with clinical, biological, and radiological improvements.
G. Morin, C. Degrugillier-Chopinet, M. Vincent, A. Fraissenon, H. Aubert, Célia Chapelle, Clément Hoguin, F. Dubos, B. Catteau, F. Petit, A. Mezel, O. Domanski, G. Herbreteau, Marie Alesandrini, N. Boddaert, N. Boutry, C. Broissand, T. Han, F. Branle, S. Sarnacki, T. Blanc, L. Guibaud, G. Canaud   +22 more
semanticscholar   +1 more source